Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 1 2000
Play
Audio Below:
That was one
of the major strong evidence of the overview, and I think it had
a lot of impact, especially in this country. Because there are a
lot of skepticism including in my own mind that tamoxifen does not
add anything in premenopausal woman who are ER-positive. But the
data is quite convincing now that in the ER-positive patients who
are premenopausal tamoxifen in the adjuvant setting does reduce
the risk of recurrence and does have a favorable impact on the survival
if the drug is given for five years.
